Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Building Japan Presence Ahead Of Crestor Loss

This article was originally published in PharmAsia News

Executive Summary

Phase III results are expected soon for a Japanese study of Brilinta, and the company hopes to have a fresh start for a new, but slow-growing product.

You may also be interested in...

Brilinta, Growing Diabetes Line-Up Spotlighted By New AstraZeneca CEO

Growth potential for AstraZeneca's new cardiovascular drug Brilinta and its diabetes franchise were highlighted by the group’s new CEO Pacal Soriot during a third-quarter analysts' call but further details of his strategic thinking must wait at least until the end of January 2013.

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts